Latest & greatest articles for insulin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on insulin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on insulin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for insulin

241. Association of Lipoproteins, Insulin Resistance, and Rosuvastatin With Incident Type 2 Diabetes Mellitus : Secondary Analysis of a Randomized Clinical Trial. Full Text available with Trip Pro

Association of Lipoproteins, Insulin Resistance, and Rosuvastatin With Incident Type 2 Diabetes Mellitus : Secondary Analysis of a Randomized Clinical Trial. Statins decrease levels of low-density lipoprotein (LDL) and triglycerides as well as cardiovascular events but increase the risk for a diagnosis of type 2 diabetes mellitus (T2DM). The risk factors associated with incident T2DM are incompletely characterized.To investigate the association of lipoprotein subclasses and size and a novel (...) lipoprotein insulin resistance (LPIR) score (a composite of 6 lipoprotein measures) with incident T2DM among individuals randomized to a high-intensity statin or placebo.This secondary analysis of the JUPITER trial (a placebo-controlled randomized clinical trial) was conducted at 1315 sites in 26 countries and enrolled 17 802 men 50 years or older and women 60 years or older with LDL cholesterol levels less than 130 mg/dL, high-sensitivity C-reactive protein levels of at least 2 mg/L, and triglyceride

2016 JAMA cardiology Controlled trial quality: predicted high

242. Percutaneous Coronary Intervention in Patients With Insulin-Treated and Non-Insulin-Treated Diabetes Mellitus: Secondary Analysis of the TUXEDO Trial. Full Text available with Trip Pro

Percutaneous Coronary Intervention in Patients With Insulin-Treated and Non-Insulin-Treated Diabetes Mellitus: Secondary Analysis of the TUXEDO Trial. Prior studies have shown that patients with insulin-treated diabetes mellitus (ITDM) have a higher risk of cardiovascular events. However, this finding is controversial, as other studies have shown that the increased risk of cardiovascular events disappears after risk adjustment. In addition, the choice of a drug-eluting stent (limus- vs taxol (...) -eluting) in ITDM is controversial, with studies showing worse outcomes with an everolimus-eluting stent compared with a paclitaxel-eluting stent.To assess the outcomes of patients with ITDM vs non-ITDM who underwent percutaneous coronary intervention and to assess the efficacy and safety of an everolimus-eluting stent vs a paclitaxel-eluting stent based on insulin use status.A prespecified analysis was conducted of the Taxus Element vs Xience Prime in a Diabetic Population (TUXEDO) clinical trial

2016 JAMA cardiology Controlled trial quality: predicted high

243. Renin–angiotensin–aldosterone system in insulin resistance and metabolic syndrome Full Text available with Trip Pro

Renin–angiotensin–aldosterone system in insulin resistance and metabolic syndrome Obesity and its consequent complications such as hypertension and metabolic syndrome are increasing in incidence in almost all countries. Insulin resistance is common in obesity. Renin- angiotensin system (RAS) is an important target in the treatment of hypertension and drugs that act on RAS improve insulin resistance and decrease the incidence of type 2 diabetes mellitus, explaining the close association

2016 Journal of translational internal medicine

244. Oral treatment with Eubacterium hallii improves insulin sensitivity in db/db mice Full Text available with Trip Pro

Oral treatment with Eubacterium hallii improves insulin sensitivity in db/db mice An altered intestinal microbiota composition is associated with insulin resistance and type 2 diabetes mellitus. We previously identified increased intestinal levels of Eubacterium hallii, an anaerobic bacterium belonging to the butyrate-producing Lachnospiraceae family, in metabolic syndrome subjects who received a faecal transplant from a lean donor. To further assess the effects of E. hallii on insulin (...) sensitivity, we orally treated obese and diabetic db/db mice with alive E. hallii and glycerol or heat-inactive E. hallii as control. Insulin tolerance tests and hyperinsulinemic-euglycemic clamp experiments revealed that alive E. hallii treatment improved insulin sensitivity compared control treatment. In addition, E. hallii treatment increased energy expenditure in db/db mice. Active E. hallii treatment was found to increase faecal butyrate concentrations and to modify bile acid metabolism compared

2016 NPJ biofilms and microbiomes

245. Heterogeneous Contribution of Insulin Sensitivity and Secretion Defects to Gestational Diabetes Mellitus Full Text available with Trip Pro

Heterogeneous Contribution of Insulin Sensitivity and Secretion Defects to Gestational Diabetes Mellitus To characterize physiologic subtypes of gestational diabetes mellitus (GDM).Insulin sensitivity and secretion were estimated in 809 women at 24-30 weeks' gestation, using oral glucose tolerance test-based indices. In women with GDM (8.3%), defects in insulin sensitivity or secretion were defined below the 25th percentile in women with normal glucose tolerance (NGT). GDM subtypes were defined (...) based on the defect(s) present.Relative to women with NGT, women with predominant insulin sensitivity defects (51% of GDM) had higher BMI and fasting glucose, larger infants (birth weight z score 0.57 [-0.01 to 1.37] vs. 0.03 [-0.53 to 0.52], P = 0.001), and greater risk of GDM-associated adverse outcomes (57.6 vs. 28.2%, P = 0.003); differences were independent of BMI. Women with predominant insulin secretion defects (30% of GDM) had BMI, fasting glucose, infant birth weights, and risk of adverse

2016 EvidenceUpdates

246. Investigating the Relationship between Insulin-like Growth Factor-1 (IGF-1) in diabetic mother’s breast milk and the blood serum of their babies Full Text available with Trip Pro

Investigating the Relationship between Insulin-like Growth Factor-1 (IGF-1) in diabetic mother’s breast milk and the blood serum of their babies Since research investigating IGF-1 levels in breast milk are few, the goal of this study was to analyze the IGF-1 levels in the breast milk of diabetic mothers as well as in the serum of their newborn babies and to identify what relationship exists between blood serum and IGF-1 milk levels through patient measurement of mothers and their babies.This

2016 Electronic physician

247. Acanthosis Nigricans and Insulin Resistance. (Abstract)

Acanthosis Nigricans and Insulin Resistance. 27305209 2016 06 30 2016 06 16 1533-4406 374 24 2016 Jun 16 The New England journal of medicine N. Engl. J. Med. IMAGES IN CLINICAL MEDICINE. Acanthosis Nigricans and Insulin Resistance. e31 10.1056/NEJMicm1508730 Lauria Marcio W MW Faculdade de Medicina da Universidade Federal de Minas Gerais, Belo Horizonte-MG, Brazil marciowlauria@gmail.com. Saad Mario J MJ Universidade Estadual de Campinas, Campinas-SP, Brazil. eng Case Reports Journal Article (...) United States N Engl J Med 0255562 0028-4793 0 Autoantibodies EC 2.7.10.1 Receptor, Insulin AIM IM Acanthosis Nigricans etiology pathology Adult Autoantibodies blood Autoimmune Diseases complications diagnosis Female Hirsutism etiology Humans Hyperglycemia etiology Hyperinsulinism etiology Insulin Resistance Receptor, Insulin immunology 2016 6 16 6 0 2016 6 16 6 0 2016 7 1 6 0 ppublish 27305209 10.1056/NEJMicm1508730

2016 NEJM

248. Insulin resistance: vascular function and exercise Full Text available with Trip Pro

Insulin resistance: vascular function and exercise Insulin resistance associated with metabolic syndrome and Type 2 diabetes mellitus is an epidemic metabolic disorder, which increases the risk of cardiovascular complications. Impaired vascular endothelial function is an early marker for atherosclerosis, which causes cardiovascular complications. Both experimental and clinical studies indicate that endothelial dysfunction in vasculatures occurs with insulin resistance. The associated (...) physiological mechanisms are not fully appreciated yet, however, it seems that augmented oxidative stress, a physiological imbalance between oxidants and antioxidants, in vascular cells is a possible mechanism involved in various vascular beds with insulin resistance and hyperglycemia. Regardless of the inclusion of resistance exercise, aerobic exercise seems to be beneficial for vascular endothelial function in both large conduit and small resistance vessels in both clinical and experimental studies

2016 Integrative medicine research

249. The Clinical and Economic Impact of the V-Go® Disposable Insulin Delivery Device for Insulin Delivery in Patients with Poorly Controlled Diabetes at High Risk Full Text available with Trip Pro

The Clinical and Economic Impact of the V-Go® Disposable Insulin Delivery Device for Insulin Delivery in Patients with Poorly Controlled Diabetes at High Risk Diabetes is a chronic condition and when poorly controlled can lead to complications and death. Patients with glycated hemoglobin (A1C) measures >9 % are at significant risk for diabetes-related complications impacting the patient's quality of life and imposing higher costs on the healthcare system. A1C reductions of 1 % or greater (...) in this population have demonstrated substantial health and economic benefits. Reducing the percent of patients at risk is an essential component of quality-care measures established for patients with diabetes.To evaluate if switching patients prescribed subcutaneous insulin injections to V-Go for insulin delivery would impact clinical and economic parameters in patients with poorly controlled diabetes (A1C > 9 %).The study was a retrospective analysis using data extracted from the electronic medical records

2016 Drugs - real world outcomes

250. Twice-daily insulin degludec/insulin aspart provides superior fasting plasma glucose control and a reduced rate of hypoglycaemia compared with biphasic insulin aspart 30 in insulin-naive adults with Type 2 diabetes Full Text available with Trip Pro

Twice-daily insulin degludec/insulin aspart provides superior fasting plasma glucose control and a reduced rate of hypoglycaemia compared with biphasic insulin aspart 30 in insulin-naive adults with Type 2 diabetes To evaluate the efficacy and safety of twice-daily insulin degludec/insulin aspart vs. twice-daily biphasic insulin aspart 30 in people with Type 2 diabetes mellitus who were naïve to insulin.In this 26-week, multinational, open-label, controlled, two-arm, parallel-group, treat (...) -to-target trial, participants [mean (± sd) age 58.9 (±8.9) years, duration of diabetes 9.5 (±5.9) years, HbA1c 68 (±8.7) mmol/mol or 8.4 (±0.8)% and BMI 31.2 (±4.2) kg/m(2) ) were randomized (1:1) to insulin degludec/insulin aspart (n = 197) or biphasic insulin aspart 30 (n = 197), administered with breakfast and the main evening meal, titrated to a self-monitored plasma glucose target > 3.9 and ≤ 5.0 mmol/l.The mean HbA1c was reduced to 49 mmol/mol (6.6%) with insulin degludec/insulin aspart and 48

2016 EvidenceUpdates Controlled trial quality: uncertain

251. New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese adults with type 1 diabetes using basal and mealtime insulin: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 1) Full Text available with Trip Pro

New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese adults with type 1 diabetes using basal and mealtime insulin: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 1) To compare efficacy and safety of new insulin glargine 300 U/ml (Gla-300) with that of insulin glargine 100 U/ml (Gla-100) in Japanese adults with type 1 diabetes.The EDITION JP 1 study (NCT01689129) was a 6-month, multicentre, open-label, phase III study. Participants (n = 243) were (...) randomized to Gla-300 or Gla-100 while continuing mealtime insulin. Basal insulin was titrated with the aim of achieving a fasting self-monitored plasma glucose target of 4.4-7.2 mmol/l. The primary endpoint was change in glycated haemoglobin (HbA1c) over 6 months. Safety measures included hypoglycaemia and change in body weight.Gla-300 was non-inferior to Gla-100 for the primary endpoint of HbA1c change over the 6-month period {least squares [LS] mean difference 0.13 % [95 % confidence interval (CI

2016 EvidenceUpdates Controlled trial quality: predicted high

252. Hepatitis C Virus, Insulin Resistance, and Steatosis Full Text available with Trip Pro

Hepatitis C Virus, Insulin Resistance, and Steatosis Hepatitis C virus (HCV) is one of the main causes of liver disease worldwide. Liver steatosis is a common finding in many hepatic and extrahepatic disorders, the most common being metabolic syndrome (MS). Over time, it has been shown that the frequent coexistence of these two conditions is not coincidental, since many epidemiological, clinical, and experimental studies have indicated HCV to be strongly associated with liver steatosis (...) and numerous metabolic derangements. Here, we present an overview of publications that provide clinical evidence of the metabolic effects of HCV and summarize the available data on the pathogenetic mechanisms of this association. It has been shown that HCV infection can induce insulin resistance (IR) in the liver and peripheral tissues through multiple mechanisms. Substantial research has suggested that HCV interferes with insulin signaling both directly and indirectly, inducing the production of several

2016 Journal of clinical and translational hepatology

253. Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes: The DUAL V Randomized Clinical Trial. Full Text available with Trip Pro

Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes: The DUAL V Randomized Clinical Trial. Achieving glycemic control remains a challenge for patients with type 2 diabetes, even with insulin therapy.To assess whether a fixed ratio of insulin degludec/liraglutide was noninferior to continued titration of insulin glargine in patients with uncontrolled type 2 diabetes treated with insulin glargine

2016 JAMA Controlled trial quality: predicted high

254. Comparative study between two recombinant human NPH insulin formulations for the treatment of type 2 diabetes mellitus. Full Text available with Trip Pro

Comparative study between two recombinant human NPH insulin formulations for the treatment of type 2 diabetes mellitus. To compare the effects of the neutral protamine Hagedorn (NPH) recombinant human insulin formulations Gansulin and Humulin N® on the glycemic control of patients with type 2 diabetes mellitus (T2DM).Prospective, double-blind, randomized, parallel, single-center study of 37 individuals with T2DM treated with NPH insulin formulations. The Tukey-Kramer test for multiple (...) comparisons, the Wilcoxon paired comparison test and the Chi-Square test were used for the statistical analyses. The significance level was set at 5% (p < 0.05).The NPH insulin formulations Humulin and Gansulin similarly reduced the HbA1c levels observed at the end of the study compared with the values obtained at the beginning of the study. In the Humulin group, the initial HbA1c value of 7.91% was reduced to 6.56% (p < 0.001), whereas in the Gansulin group, the reduction was from 8.18% to 6.65% (p

2016 Archives of endocrinology and metabolism Controlled trial quality: uncertain

255. Insulin Resistance and a Long, Strange Trip. (Abstract)

Insulin Resistance and a Long, Strange Trip. 26886417 2016 04 13 2018 12 02 1533-4406 374 14 2016 Apr 07 The New England journal of medicine N. Engl. J. Med. Insulin Resistance and a Long, Strange Trip. 1378-9 10.1056/NEJMe1600962 Semenkovich Clay F CF From the Division of Endocrinology, Metabolism and Lipid Research, Washington University, St. Louis. eng Editorial Comment 2016 02 17 United States N Engl J Med 0255562 0028-4793 0 Hypoglycemic Agents 0 Thiazolidinediones AIM IM N Engl J Med (...) . 2016 Apr 7;374(14):1321-31 26886418 Female Fractures, Bone chemically induced Humans Hypoglycemic Agents therapeutic use Insulin Resistance Ischemic Attack, Transient drug therapy Male Myocardial Infarction prevention & control Stroke drug therapy Thiazolidinediones therapeutic use 2016 2 18 6 0 2016 2 18 6 0 2016 4 14 6 0 ppublish 26886417 10.1056/NEJMe1600962

2016 NEJM

256. Insulin Pumps for Adults with Type 1 Diabetes: A Review of Clinical Effectiveness, Cost-effectiveness and Guidelines

Insulin Pumps for Adults with Type 1 Diabetes: A Review of Clinical Effectiveness, Cost-effectiveness and Guidelines Insulin Pumps for Adults with Type 1 Diabetes: A Review of Clinical Effectiveness, Cost-effectiveness and Guidelines | CADTH.ca Find the information you need Insulin Pumps for Adults with Type 1 Diabetes: A Review of Clinical Effectiveness, Cost-effectiveness and Guidelines Insulin Pumps for Adults with Type 1 Diabetes: A Review of Clinical Effectiveness, Cost-effectiveness (...) and Guidelines Published on: December 10, 2015 Project Number: RC0731-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the comparative clinical effectiveness of insulin pumps versus multiple daily injections for adults with type 1 diabetes? What is the comparative clinical effectiveness of insulin pump models with continuous glucose monitors versus standard insulin pumps for adults with type 1 diabetes? What is the cost-effectiveness

2016 Canadian Agency for Drugs and Technologies in Health - Rapid Review

257. Randomised controlled trial: Blood glucose monitoring had no impact on distress or self-efficacy in people with non-insulin-treated type 2 diabetes

Randomised controlled trial: Blood glucose monitoring had no impact on distress or self-efficacy in people with non-insulin-treated type 2 diabetes Blood glucose monitoring had no impact on distress or self-efficacy in people with non-insulin-treated type 2 diabetes | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please (...) see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Blood glucose monitoring had no impact on distress or self-efficacy in people with non-insulin-treated type 2 diabetes

2016 Evidence-Based Medicine

258. Randomized clinical trial: Detemir is non-inferior to NPH insulin in women with pregestational type 2 diabetes and gestational diabetes mellitus

Randomized clinical trial: Detemir is non-inferior to NPH insulin in women with pregestational type 2 diabetes and gestational diabetes mellitus Detemir is non-inferior to NPH insulin in women with pregestational type 2 diabetes and gestational diabetes mellitus | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see (...) our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Detemir is non-inferior to NPH insulin in women with pregestational type 2 diabetes and gestational diabetes mellitus Article

2016 Evidence-Based Medicine

259. Diabetes Technology: Continuous Subcutaneous Insulin Infusion Therapy and Continuous Glucose Monitoring in Adults

Diabetes Technology: Continuous Subcutaneous Insulin Infusion Therapy and Continuous Glucose Monitoring in Adults '); '); Diabetes Technology Guideline Resources | Endocrine Society Hormone Science to Health / › › › Guidelines and Clinical Practice Section + Diabetes Technology Guideline Resources Full Guideline: JCEM | September 2016 Anne L. Peters (chair), Andrew J. Ahmann, Tadej Battelino, Alison Evert, Irl B. Hirsch, M. Hassan Murad, William E. Winter, and Howard Wolpert The 2016 guideline (...) on Diabetes Technology addresses: Matching individuals to the best-suited technological solutions for type 1 and type 2 diabetes management Deciding when individuals would benefit from continuous subcutaneous insulin infusion (CSII) and real-time continuous glucose monitoring (RT-CGM) Assessing and re-assessing individual psychological status, self-care behavior, and education and training before and during use to ensure adherence and maximize successful adoption of technology Resources | ENDO 2016

2016 The Endocrine Society

260. Insulin glargine (Abasaglar®)

Insulin glargine (Abasaglar®) Insulin glargine (Abasaglar®) Insulin glargine (Abasaglar®) All Wales Medicines Strategy Group (AWMSG) Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation All Wales Medicines Strategy Group (AWMSG). Insulin glargine (Abasaglar®) Penarth: All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines (...) Strategy Group (AWMSG). AWMSG Secretariat Assessment Report Advice No. 2307. 2015 Authors' conclusions Insulin glargine (Abasaglar®) is recommended as an option for restricted use within NHS Wales for the treatment of diabetes mellitus in adults, adolescents and children aged 2 years and above. Insulin glargine (Abasaglar®) should be prescribed within its licensed indication in accordance with NICE or AWMSG guidance for insulin glargine (Lantus®), the reference product. Insulin glargine (Abasaglar®

2016 Health Technology Assessment (HTA) Database.